• GPhC registered UK pharmacy
  • Free clinical support
  • Discreet delivery

Wegovy Pill Results: How Much Weight Could You Lose?

Quick answer: In the OASIS-4 trial, adults taking the licensed 25 mg Wegovy pill lost an average of 13.6% of their starting body weight after 64 weeks, compared with 2.2% with placebo. The average reduction was 14.2 kg, and 76.3% of participants lost at least 5%. A separate analysis estimated 16.6% weight loss if everyone had remained on treatment without other weight-loss therapies. These are group averages, not personal predictions, and results vary.
13.6%average weight loss in the main OASIS-4 analysis
14.2 kgaverage reduction from starting weight
76.3%of participants lost at least 5%
64 weekslength of the OASIS-4 trial
Content last updated: 10 November 2026
Clinical Evidence

1. What the OASIS-4 Trial Found

OASIS-4 studied 307 adults with overweight or obesity who did not have diabetes. All participants were supported to follow a reduced-calorie diet and increase physical activity. Of these, 205 received oral semaglutide and 102 received placebo for 64 weeks.
OASIS-4 result at week 64Wegovy pill 25 mgPlacebo
Average change in body weight-13.6%-2.2%
Average change from starting weight-14.2 kg-2.2 kg
Lost at least 5%76.3%30.5%
Lost at least 10%59.8%14.1%
Lost at least 15%47.0%5.4%
Lost at least 20%27.5%3.0%
The 13.6% figure reflects the main analysis of everyone assigned to treatment, including people who stopped taking it. A separate analysis estimated a 16.6% average reduction with oral semaglutide and 2.8% with placebo if everyone had remained on their assigned treatment without other weight-loss therapies. This explains why both figures appear in information about the medicine.
What these results do and do not showTrial averages describe groups of participants. They cannot predict exactly how much one person will lose or how quickly it will happen. Your response can be lower or higher, and your prescriber should review progress, side effects and whether treatment remains suitable.
Illustrative Examples

2. What 13.6% Weight Loss Could Mean

The examples below apply the OASIS-4 group average of 13.6% to three starting weights. They are simple calculations to help explain the percentage, not forecasts of personal results.
Starting weight13.6% of starting weightIllustrative weight after loss
90 kg12.2 kg77.8 kg
110 kg15.0 kg95.0 kg
130 kg17.7 kg112.3 kg
Use the percentage carefullyClinical-trial participants differed in starting weight, health, adherence and response. Reaching a particular dose does not guarantee a particular percentage or kilogram loss.
Timing

3. When Might Wegovy Pill Results Become Noticeable?

There is no reliable week-by-week kilogram target for an individual. In OASIS-4, average weight loss began early and continued across the 64-week study, but the published evidence does not support promising a fixed amount in month one, month three or month six.Treatment starts at 1.5 mg once daily. If it is tolerated and your prescriber agrees, the licensed schedule can increase to 4 mg, 9 mg and then 25 mg, with at least one month at each dose. This gradual schedule means that the first months are also an adjustment period. Follow the prescribed Wegovy pill dosage and the fasting and water instructions for taking the Wegovy pill.
Do not change the dose yourselfTaking more than prescribed or increasing early does not guarantee faster weight loss and may increase side effects. Contact your prescriber if you are unsure about the schedule or your response.
Individual Response

4. What Can Affect Your Results?

  • Taking it correctly: food, drinks and other oral medicines can affect absorption, so the daily routine matters.
  • Your prescribed dose and time on treatment: the maintenance dose is reached gradually and only if suitable.
  • Eating pattern and activity: the medicine is licensed alongside a reduced-calorie diet and increased physical activity. Our nutrition guide explains what to eat while using Wegovy.
  • Side effects and missed doses: nausea, vomiting, diarrhoea or constipation can make it harder to follow the plan. Read about Wegovy pill side effects and ask for help if symptoms persist.
  • Body composition: resistance exercise and adequate nutrition can help protect muscle while taking the Wegovy pill.
  • Individual biology and health: starting weight, medical conditions, medicines, sleep and other factors can all affect response.
Treatment Comparison

5. How Wegovy Pill Results Compare With Wegovy Injections

The 25 mg Wegovy pill and 2.4 mg Wegovy injection have not been compared directly in a head-to-head weight-loss trial. Results from separate trials can provide context, but differences in participants, duration and analysis mean they should not be treated as a ranking.
TreatmentStudyAverage weight changeDuration
Wegovy pill 25 mgOASIS-4-13.6% in the main analysis64 weeks
Wegovy injection 2.4 mgSTEP 1-14.9% in the main analysis68 weeks
The most suitable formulation depends on clinical suitability, the daily tablet routine, weekly injection preference, side effects and prescriber advice. Our Wegovy pill vs injection guide compares the practical differences.
Progress Reviews

6. What If Your Weight Loss Is Slower Than Expected?

A slower result does not automatically mean treatment has failed. Do not increase the dose or combine weight-loss medicines yourself. Your prescriber can review how you take the tablet, the dose schedule, side effects, eating and activity patterns, other medicines and health factors that may affect progress.It is also sensible to consider affordability and whether the daily routine remains realistic. See the current Wegovy pill price and read about long-term Wegovy pill treatment before deciding what to discuss at your next review.
Bring useful information to your reviewRecord your weight at consistent intervals, any missed doses, side effects and questions about the routine. This gives the prescriber a clearer picture than reacting to one short-term reading.
Common Questions

Frequently Asked Questions

In OASIS-4, adults taking licensed 25 mg oral semaglutide lost 13.6% of their starting weight on average after 64 weeks in the main analysis. The average reduction was 14.2 kg. Individual results varied, and the figures are not a personal prediction.
Average weight loss began early and continued through the 64-week OASIS-4 trial, but there is no evidence-based fixed number of kilograms that everyone should lose in a particular month. The dose is increased through the first three months before the maintenance dose, if tolerated and prescribed.
The 13.6% figure comes from the main analysis of all participants assigned to the 25 mg tablet, including those who stopped treatment. The 16.6% figure is a separate estimate of what may have happened if everyone had remained on treatment without other weight-loss therapies.
Keep taking the medicine exactly as prescribed and contact your prescriber for a review. They can check the administration routine, dose, side effects, eating and activity patterns, other medicines and whether ongoing treatment is suitable. Do not increase the dose yourself.
There has not been a direct head-to-head weight-loss trial of the licensed 25 mg tablet and 2.4 mg injection. Separate trials produced similar group averages, but they involved different study designs and should not be used to guarantee equivalent results.
Weight regain can occur after weight-management medicines are stopped because appetite and other biological drivers may return. Discuss a maintenance plan with your prescriber rather than stopping suddenly. Our guide to long-term Wegovy pill use explains the considerations.
Considering the Wegovy Pill?Complete a confidential online consultation. A UK prescriber will review your health, current medicines and treatment goals before deciding whether the Wegovy pill is suitable.Start Your Wegovy Pill Assessment →

References

  1. Wegovy tablets Summary of Product Characteristics. Licensed indication, dosage, administration and OASIS-4 clinical results.
  2. MHRA. First GLP-1 tablet for weight loss approved in the UK. UK approval and clinical-trial summary.
  3. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. STEP 1 results for injected semaglutide.
  4. NICE TA875. Semaglutide for managing overweight and obesity. UK guidance for the injected formulation.
  5. General Pharmaceutical Council. Happy Pharmacy registration.

Medically Reviewed by Our GPhC-Registered Pharmacists

GPhC Logo National Pharmacy Association Logo
Palvinder Deol

Authored by:

Palvinder Deol
Superintendent Pharmacist
Over 25 years' clinical experience.
Nigel Howard

Reviewed by:

Nigel Howard
Independent Prescriber
Over 20 years' clinical experience.